Skip to main content
SpringerPlus
Fig. 2 | SpringerPlus

Fig. 2

From: The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis

Fig. 2

Quality of life outcome in both groups on five functional scales (physical, emotional, social, sexual functioning and general quality of life) and six symptom scales (nausea, pain, urinary, bowel and treatment related symptoms) at screening, 3, 6 and 12 months of treatment. A high score for general quality of life or a functional scale reflects a high QoL or a high level of functioning, whereas a high score for a symptoms scale implies a high level of symptoms

Back to article page